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INTRODUCTION
Systemic inflammatory response to infection complicated
with consecutive multiple organ failure is a major sign of
severe sepsis (Levy, 2003). Severe sepsis is the leading
cause of ICU (Intensive Care Unit) mortality worldwide
(Angus, 2001).
IL-6 has been found to be a key cytokine in the pathogene-
sis of severe sepsis. The main biological effects of IL-6 are
stimulation of B- and T-lymphocytes and induction of fever
and acute phase response (Borden and Chin, 1994). Several
studies have demonstrated a correlation of IL-6 serum con-
centration with severity and outcome in septic patients
(Schlüter et al., 1991, Casey, 1993).
Genetic variation within the promoter region of IL-6 gene
may affect the severity and outcome of sepsis. Recently,
several variations of the IL-6 gene promoter region were de-
scribed (Fishman et al., 1998). A polymorphism at -174 po-
sition of IL-6 promoter region with a G to C substitution
(-174 G/C) shows functional significance in some inflam-
matory diseases and other clinical conditions (Flex, 2002;
Balding, 2004).
In severe sepsis patients the functional significance of -174
remains unclear. In studies with healthy individuals contra-
dicting results were observed. Benermo et al. reported sig-
nificantly higher plasma IL-6 values in individuals with G
genotype after vaccination with 1 mL of Salmonella typhii
vaccine (Bennermo et al., 2004). Endler et al. found no dif-
ferences in serum IL-6 level after LPS infusion in individu-
als with C and G genotype (Endler, 2004).
According to IL-6 (-174C) association with susceptibility
and clinical outcome Shlüter et al. found no difference in
genotype distribution between septic patients and healthy
controls (Schlüter et al., 2002). In nonsurvivors signifi-
cantly less GG homozygotes were observed compared with
survivors and median systemic IL-6 levels in septic patients
were closely correlated with outcome but were not associ-
ated with the IL-6 promoter genotype.
A bialelic polymorphism at promoter -174 position may be
associated with a certain (low or high) IL-6 producer pheno-
type and determinate interindividual variation in IL-6 medi-
ated pathology.
We tested the hypothesis that the alternative allele (-174C)
is associated with IL-6 systemic level and clinical outcome
in patients with severe sepsis.
MATERIAL AND METHODS
The study was conducted in the tertiary mixed medical-
surgical adult ICU of Pauls Stradiòð Clinical University
Hospital in Rîga in 2007. Patient data were screened daily
and patients were included in the study cohort (n = 103) if
they met proposed severe sepsis criteria (Levy et al., 2003)
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and were successfully genotyped at -174C/G SNP of IL-6
gene. Patients were included in this cohort on the calendar
day that severe sepsis criteria were met. Ethical approval
was obtained and all subjects consented to participate in the
study.
The plasma of these patients was tested for IL-6 concentra-
tion by immunoassay (Biosorce Europe S.A. IL-6, EASIA)
at the day of inclusion in this study.
The IL-6 promoter polymorphism -174 G/C was analysed
as follows. Genomic DNA was extracted from peripheral
blood sample using standard phenol-chloroform extraction
method. The IL-6 promoter region harbouring the polymor-
phism of our interest was PCR amplified. For PCR amplifi-
cation we used template DNA, forward primer
5’-TCGTGCATGACTTCAGCTTT-3’, reverse primer
5’-GCCTCAGACATCTCCAGTCC-3’ and PCR
MasterMix (2 x) (Fermentas Life Sciences). The cycling
conditions of PCR were as follows: 5 minutes of initial de-
naturation at 95 oC, following 32 cycles of 15 seconds at 95
oC, 30 seconds at 56 oC, 30 seconds at 72 oC, and final ex-
tension—10 minutes at 72 oC. PCR products were then pu-
rified. We used the primer sequence
5’-TCATGGGAAAATCCCACATT-3’ for sequencing re-
action. Products were analysed by direct sequencing using a
3100 ABI prism DNA sequencer according to recommenda-
tions from the manufacturer.
Patients were followed up throughout their stay in the ICU
to the clinical outcome.
Descriptive statistics were used for basic characterisation of
the patient groups according to genotypes. Nonparametric
statistics were applied. All statistical comparisons between
groups were done with the Kruskal–Wallis test and the
Mann–Whitney U-test. All statistical calculations were per-
formed with commercially available statistical software
(„SPSS 15.0 for Windows”; SPSS Inc.). A value of P <
0.05 was considered to indicate a statistical significance.
RESULTS
The demographic and clinical data at the day of inclusion of
103 Caucasian patients enrolled in this study are summa-
rised in Table 1. The main reasons of severe sepsis were
respiratory tract (82%) and abdominal (15%) infections.
The overall survival was 59 (57.3%) of 103 patients en-
rolled. Demographic data of the study population did not
differ significantly between survivor and nonsurvivor
groups.
We evaluated the association of IL-6 promoter polymor-
phism (-174 G/C) with outcome of severe sepsis. There
was no significantly different distribution of genotypes be-
tween surviving and nonsurviving severe sepsis patients
(Table 2). Comparing IL-6 median levels in surviving and
nonsurviving severe sepsis patients, IL-6 plasma concentra-
tion was significantly increased in nonsurvivors. In survi-
vors the median IL-6 level was 190 pg/mL (5th/95th percen-
tiles: 28/2024), whereas in nonsurviving patients 450
pg/mL (5th/95th percentiles: 60/2024), with P < 0.01
(Mann-Whitney U test).
We also tested the association of IL-6 promoter polymor-
phisms (-174 G/C) with IL-6 median concentration in survi-
vors and nonsurvivors (Table 3). There was no association
of genotype with median IL-6 plasma level in surviving se-
vere sepsis patients (P > 0.05, Kruskal-Wallis test), but in
nonsurvivors we found significant differences between
groups stratified by genotypes (P = 0.01, Kruskal-Wallis
test). A significantly increased median IL-6 plasma level
was observed in nonsurviving patients with GG genotype—
1372 pg/mL (5th/95th percentiles: 200/2024), compared
with C/C (240 pg/mL, 20/2024) and C/G (440 pg/mL,
60/2024).
DISCUSSION
In our study we found no significantly different distribution
of IL-6 promoter genotypes between surviving and nonsur-
viving severe sepsis patients. Thus, we were not able to
confirm the previously reported associations between IL-6
(-174 G/C) polymorphism and outcome in severe sepsis pa-
tients (Schlüter et al., 2002; Tischendorf et al., 2007). A
possible explanation for this is that other factors (e.g. pre-
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T a b l e 1
CHARACTERISTICS OF THE PATIENTS1
Survivors (n = 59) Nonsurvivors (n = 44)
Male patients (% of total) 45 (58) 32 (42)
Age (years) 64 ±5,4 72 ±8,2
SOFA 6 ±4 9 ±4
ICU stay (days) 4 ±3 12 ±8
MPV days 3 ±2 11 ±5
¹ All values except gender are the mean (±SD)
T a b l e 2
INTERLEUKINE-6 PROMOTER POLYMORPHISM (-174G/C) AND










P > 0.05, Chi-square 5.36
T a b l e 3
INTERLEUKINE-6 PROMOTER POLYMORPHISM (-174G/C) AND
IL-6 MEDIAN CONCENTRATION IN SURVIVORS AND
NONSURVIVORS1









1All values are median (5th/95th percentiles)
2
P = 0.01, Chi-square 9.21
existing disease, initial insult, therapeutic intervention etc.)
influence the outcome.
We did find a significant difference in IL-6 plasma level be-
tween survivors and nonsurvivors, as reported previously
(Schlüter et al., 2002).
We found an association between genotype and the IL-6
level in nonsurviving patients, but not in surviving patients.
In nonsurvivors a significantly increased IL-6 plasma level
was found in patients with the G/G genotype. The observed
association of G/G genotype with IL-6 level in the nonsur-
viving subgroup suggests a possible function of the G/G
genotype under specific clinical conditions (e.g., high level
of IL-6 gene stimulation). Our observations confirm the pre-
viously reported association of G allele and increased IL-6
expression in healthy volunteers (Bennermo et al., 2004).
Both in surviving and nonsurviving groups we observed the
highest IL-6 level in the GG genotype, followed by the CG
genotype and lowest in patients with the C/C genotype. A
similar distribution of IL-6 levels was previously reported
(Tischendorf et al., 2007).
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INTERLEIKÎNA 6 (IL-6) GÇNA (-174 G/C) PROMOTERA POLIMORFISMA ASOCIÂCIJA AR IL-6 LÎMENI UN KLÎNISKO
IZNÂKUMU SMAGAS SEPSES SLIMNIEKIEM
Interleikîns 6 (IL-6) ir nozîmîgs citokîns smagas sepses patoìençzç. IL-6 gçna promotera polimorfisma klîniskâ nozîme smagas sepses
slimniekiem arvien paliek neskaidra. Pçtîjuma mçríis ir noskaidrot IL-6 gçna promotera (-174 G/C) polimorfisma ietekmi uz IL-6
sistçmisko lîmeni un klînisko iznâkumu smagas sepses slimniekiem. Pçtîjumâ tika iekïauti 103 Paula Stradiòa Klîniskâs universitâtes
slimnîcas Intensîvâs terapijas un reanimâcijas nodaïas slimnieki ar apstiprinâtu smagas sepses diagnozi. Pçtîjuma rezultâtâ nav konstatçtas
genotipu sadalîjuma atðíirîbas izdzîvojuðiem un miruðajiem smagas sepses slimniekiem. Novçrota augstâka IL-6 plazmas koncentrâcija
miruðo slimnieku apakðgrupâ. Genotipu saistîba ar IL-6 plazmas lîmeni konstatçta miruðo slimnieku apakðgrupâ. Pçtîjuma rezultâti liecina
par IL-6 (-174 G/C) polimorfisma funkcionâlo nozîmîgumu neizdzîvojuðiem smagas sepses slimniekiem.
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